| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
α4β2 nAChR (partial agonist; EC50 2.3 µM, efficacy 13.4% relative to acetylcholine); α7 nAChR (full agonist; EC50 18 µM, efficacy 93%).
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
Varenicline is a partial agonist at α4β2 nAChRs with an EC50 of 2.3 µM and an efficacy of 13.4% relative to acetylcholine. It is a full agonist at α7 nAChRs with an EC50 of 18 µM and efficacy of 93%. It binds to α4β2 with high affinity (Ki ~0.06 nM in some assays) and shows selectivity over α3β4 and muscle-type nAChRs. |
| ln Vivo |
In vivo, varenicline reduces nicotine self-administration and relapse in animal models. It attenuates alcohol-seeking behavior and dopamine release in alcohol-dependent rats. It is effective for smoking cessation in humans at doses of 0.5–2 mg/day.
|
| Enzyme Assay |
nAChR binding is measured using membranes from cells expressing recombinant α4β2 or α7 nAChRs and a radiolabeled agonist such as [³H]-epibatidine or [³H]-nicotine. Varenicline is tested at 0.01 nM–100 µM, and Ki values are determined.
|
| Cell Assay |
In vitro functional assays use HEK293 or Xenopus oocytes expressing α4β2 or α7 nAChRs. Varenicline (0.1–100 µM) is applied, and agonist-evoked currents or calcium influx is measured by patch clamp or fluorimetry.
|
| Animal Protocol |
Rodent models of nicotine dependence receive varenicline by subcutaneous or oral administration at 0.1–3 mg/kg. Nicotine self-administration, relapse, and dopamine release are assessed. Plasma and brain concentrations are quantified by LC-MS/MS using the d4-labeled internal standard.
|
| References |
|
| Molecular Formula |
C13H13N3
|
|---|---|
| Molecular Weight |
211.262422323227
|
| Exact Mass |
215.136
|
| CAS # |
2183239-01-0
|
| Related CAS # |
Varenicline;249296-44-4
|
| PubChem CID |
71752935
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
400.6±40.0 °C at 760 mmHg
|
| Flash Point |
196.1±27.3 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.667
|
| LogP |
0.74
|
| tPSA |
37.8
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
16
|
| Complexity |
254
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C12=CC3=NC=CN=C3C=C1C1C([H])([H])NC([H])([H])C2C1
|
| InChi Key |
JQSHBVHOMNKWFT-KXGHAPEVSA-N
|
| InChi Code |
InChI=1S/C13H13N3/c1-2-16-13-5-11-9-3-8(6-14-7-9)10(11)4-12(13)15-1/h1-2,4-5,8-9,14H,3,6-7H2/i6D2,7D2
|
| Chemical Name |
13,13,15,15-tetradeuterio-5,8,14-triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2,4,6,8,10-pentaene
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.7335 mL | 23.6675 mL | 47.3350 mL | |
| 5 mM | 0.9467 mL | 4.7335 mL | 9.4670 mL | |
| 10 mM | 0.4734 mL | 2.3668 mL | 4.7335 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.